The Centre for Health Protection (CHP) of the Department of Health (DH) said today (September 14) that it is investigating a confirmed Mpox (also known as Monkeypox) case, and strongly urged high-risk target groups to receive Mpox vaccinations. Meanwhile, the public is advised to be vigilant and avoid close physical contact with individuals suspected of contracting Mpox.
 
     The case involves a 31-year-old male who developed general malaise, and rash on his palms, soles and genital area on September 9. He sought medical attention at a social hygiene service clinic (SocHS) under the DH on the next day (September 10) and has been arranged by the CHP to receive isolation treatment at Princess Margaret Hospital. Upon laboratory testing by the CHP's Public Health Laboratory Services Branch, his clinical specimen tested positive for the monkeypox virus. The patient is currently in stable condition.　
　　
     According to information provided by the patient, he had high-risk exposures with male strangers both overseas and in Hong Kong during the incubation period. No epidemiological linkages between this case and confirmed Mpox cases earlier recorded in Hong Kong have been identified so far. The CHP is continuing an epidemiological investigation of the case, and will endeavour to contact individuals who had high-risk contact with the patient and report the case to the World Health Organization.
 
     Since 2022, Hong Kong has recorded a total of 104 Mpox cases (82 local cases and 22 imported cases), including the above-mentioned case. All patients were males. Since this August, the number of Mpox cases in Hong Kong has seen an increase. As at today, 20 cases have been recorded this year, including 15 local cases and five imported cases. Among them, 11 are new cases reported since August. Epidemiological investigations showed that among the 11 recently identified cases, all patients self-identified as men who have sex with men or bisexual men. No epidemiological links were found between the cases. All patients reported engaging in high-risk sexual behaviour during the incubation period, including having sex with strangers or having sex without a condom. The CHP has sent a letter to doctors in Hong Kong, reminding them to be vigilant for Mpox cases and to provide relevant recommendations regarding Mpox vaccination to high-risk individuals.
 
     The Mpox vaccine can prevent infection and severe disease. The DH provides Mpox vaccination services for high-risk groups. The following high-risk target groups are eligible for Mpox vaccinations on a voluntary basis:

 

1. individuals with high-risk sexual practices, e.g. having multiple sexual partners, sex workers, or having a history of sexually transmitted infection within the past 12 months;
2. healthcare workers responsible for caring for patients with confirmed Mpox;
3. laboratory personnel handling zoonotic pox viruses; and
4. animal care personnel with high risk of exposure in case of Mpox occurrences in animals in Hong Kong.

 
     High-risk target groups can receive Mpox walk-in vaccinations at any of the DH's SocHS (namely Chai Wan SocHS, Wan Chai Male SocHS, Wan Chai Female SocHS, Yau Ma Tei Male SocHS, Yau Ma Tei Female SocHS, Yung Fung Shee SocHS, Fanling SocHS and Tuen Mun SocHS) and the DH's Yau Ma Tei Integrated Treatment Centre, without prior appointments.
 
     Meanwhile, the DH's Kowloon Bay Integrated Treatment Centre and the Hospital Authority's Special Medical Clinics at Queen Elizabeth Hospital and Princess Margaret Hospital also provide Mpox vaccination services for their clients.
 
     Mpox is not transmitted through respiratory droplets or aerosols in general, and transmission would not occur through social contact. The CHP reminds the public, especially those at higher risks of exposure, to take precautions and avoid close physical contact with persons or animals suspected of being infected. They should seek medical attention as soon as possible if they experience relevant symptoms, including rash, fever, chills, swollen lymph nodes, exhaustion, muscle pain, and severe headaches. They should not engage in activities with others that may involve contact with skin rash or body fluids.
 
     For more details, please visit the CHP's webpages on Mpox and Mpox Vaccination Programme.

Ends/Monday, September 14, 2026
Issued at HKT 19:40

NNNN